Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/209127
Title: | Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma |
Author: | Martinez, Carmen Haro, Manuel Espeso de Romero, Samuel Gutierrez, Antonio Domingo Domenech, Eva González Rodríguez, Ana P. Zeberio, Izaskun Martínez Badas, María Paz Rodríguez Izquierdo, Antonia Carpio, Cecilia Bastos Oreiro, Mariana Hernandez Rivas, Jose Angel Vallansot, Rolando Kelleher, Nicholas Díaz Gálvez, Francisco J. Torrado, Tamara Pereira, Arturo Garcia Sanz, Ramon |
Keywords: | Malaltia de Hodgkin Autotrasplantament Hodgkin's disease Autotransplantation |
Issue Date: | 12-Nov-2022 |
Publisher: | Springer Science and Business Media LLC |
Abstract: | The AETHERA trial demonstrated that brentuximab vedotin (BV) consolidation after autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma (HL) at high risk of relapse/progression increases progression-free survival (PFS). Patients previously exposed to BV were excluded from that trial. However, BV alone or in combination with chemotherapy is frequently used as front-line treatment and/or pre-ASCT salvage therapy. We analyzed data from 156 patients with high-risk HL who underwent ASCT with (BV-CON, n?=?62) or without (non-BV, n?=?94) BV consolidation. Fifty-seven patients received BV-based salvage regimens before ASCT. The 3-year overall survival and PFS for all patients were 91.6% and 70.0%, respectively. Multivariate analysis showed that BV-CON was associated with better PFS (HR 0.39, p?=?0.01), whereas positive PET at transplant leaded to worse PFS (HR 2.71, p?=?0.001). BV-CON improved PFS in PET-positive patients (72.2% vs. 43.0%, p?=?0.05), with a beneficial trend observed in PET negative (88.8% vs. 75.2%, p?=?0.09). BV-CON patients with or without BV exposure pre-ASCT had a significantly better PFS than non-BV with or without BV pretransplant treatment (HR 0.36, p?=?0.004). The efficacy of real-life BV consolidation therapy was similar to that in the AETHERA trial. This therapeutic strategy improves survival independently of BV exposure prior to ASCT.© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
Note: | Reproducció del document publicat a: https://doi.org/10.1007/s00277-022-05011-6 |
It is part of: | Annals Of Hematology, 2023, vol. 102, num. 2, p. 429-437 |
URI: | http://hdl.handle.net/2445/209127 |
Related resource: | https://doi.org/10.1007/s00277-022-05011-6 |
ISSN: | 1432-0584 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
BrCON-GELTAMO_AnnHematol_Final_CMartinez.pdf | 330.6 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.